GMO Research & AI,Inc. AI Stock Analysis
Want to see JP:3695 full AI Analyst Report?
GMO Research & AI,Inc. (3695) AI Stock Analysis
GMO Research & AI,Inc.
(TSE/TYO:3695)
The overall score of 53 reflects a company with strong cash generation and an attractive valuation, offset by significant technical weakness and declining profitability. The most impactful positive factor is the high dividend yield and low P/E ratio, which suggest good value. However, the stock's price is in a clear downtrend below all major moving averages, and the financial performance is hampered by a multi-year low in net income despite robust revenue growth. The surge in liabilities also presents a risk that tempers the positive cash flow story.
GMO Research & AI,Inc. (3695) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.26B
- Dividend Yield
- 4.47%
- Average Volume (3M)
- 24.85K
- Price to Earnings (P/E)
- 10.0
- Beta (1Y)
- 0.72
- Revenue Growth
- 21.08%
- EPS Growth
- 86.42%
- Country
- Japan
- Employees
- 199
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Specialty Business Services
GMO Research & AI,Inc. Business Overview & Revenue Model
Company Description
Established in 2002 and headquartered in Tokyo, Japan, GMO Research & AI, Inc. delivers an audience engagement platform to a global and domestic Japanese clientele. Central to its offering is the Asia Cloud Panel, an extensive online network comprisi...
GMO Research & AI,Inc. Financial Statement Overview
Summary
Financial performance is mixed. Revenue growth and gross margin expansion are strong, but net income has fallen to a six-year low due to rising expenses. The balance sheet shows a manageable debt-to-equity ratio of 0.27, yet total liabilities surged, and operating cash flow covers only 15.1% of them. Cash flow generation was exceptional, with operating cash flow up 317% and free cash flow conversion at 99.5%, indicating high earnings quality.
Income Statement
45NeutralBalance Sheet
50NeutralCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.37B | 6.82B | 5.03B | 5.12B | 5.20B | 4.09B |
| Gross Profit | 4.34B | 3.83B | 2.55B | 2.54B | 2.46B | 1.98B |
| EBITDA | 916.88M | 489.82M | 340.09M | 529.91M | 505.32M | 421.41M |
| Net Income | 458.34M | 155.64M | 183.15M | 307.31M | 356.38M | 274.06M |
Balance Sheet | ||||||
| Total Assets | 10.54B | 9.46B | 3.01B | 2.99B | 3.07B | 2.80B |
| Cash, Cash Equivalents and Short-Term Investments | 6.98B | 5.52B | 1.19B | 1.33B | 1.17B | 1.26B |
| Total Debt | 901.32M | 650.22M | 5.50M | 12.22M | 16.80M | 19.29M |
| Total Liabilities | 8.03B | 7.00B | 892.65M | 946.14M | 1.16B | 1.12B |
| Stockholders Equity | 2.48B | 2.43B | 2.10B | 2.05B | 1.91B | 1.68B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 986.28M | 236.43M | 474.82M | 128.69M | 472.10M |
| Operating Cash Flow | 0 | 990.78M | 237.50M | 475.49M | 131.65M | 482.16M |
| Investing Cash Flow | 0 | -379.84M | -221.00M | -131.49M | -111.34M | -50.65M |
| Financing Cash Flow | 0 | 455.83M | -195.90M | -187.50M | -145.31M | -96.53M |
GMO Research & AI,Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3695, the sentiment is Neutral. The current price of 1333.00 is below the 20-day moving average (MA) of 1338.80, below the 50-day MA of 1487.46, and below the 200-day MA of 1607.52, indicating a bearish trend. The MACD of -84.39 indicates Positive momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 59.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3695.
GMO Research & AI,Inc. Peers Comparison
Overall Rating
JP:608881Outperform
JP:434673Outperform
JP:618365Neutral
JP:781463Neutral
JP:369553Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | JPY 54.71B | 14.85 | ― | 4.00% | -13.49% | -14.46% | |
| 73Outperform | JPY 9.68B | 7.28 | ― | 4.03% | 8.49% | 26.99% | |
| 65Neutral | JPY 104.55B | 12.25 | ― | 4.27% | 0.78% | -2.52% | |
| 63Neutral | JPY 26.26B | 4.64 | ― | 6.66% | 11.59% | 88.95% | |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| 53Neutral | JPY 5.87B | 9.97 | ― | 4.47% | 21.08% | 86.42% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3695 | GMO Research & AI,Inc. | 1333.00 | -658.58 | -33.07% | |
| JP:4346 | NEXYZ.Group Corporation | 744.00 | -173.90 | -18.95% | |
| JP:6088 | SIGMAXYZ Holdings Inc | 650.00 | -80.65 | -11.04% | |
| JP:6183 | BELLSYSTEM24 Holdings, Inc. | 1406.00 | 118.64 | 9.22% | |
| JP:7814 | JAPAN Creative Platform Group Co., Ltd. | 567.00 | -196.41 | -25.73% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
